Feb 21, 2012 by Brian Orelli, PhDDon't Worry about Missing this 50% PopCorcept's Korlym gets approved, but investors who sat it out shouldn't feel bad.
Feb 17, 2012 by Brian Orelli, PhDNo Way? Obesity Drugs Have Side EffectsFDA still worried about side effects of VIVUS' Qnexa
Feb 17, 2012 by Brian Orelli, PhD1 Biotech Punished by Hep-C OverreactionGilead slips, but hasn't fallen yet.
Feb 16, 2012 by Brian Orelli, PhDA Multibillion-Dollar Market Filled With UnknownsInvestors should consider biosimilars as icing on the cake.
Feb 16, 2012 by Brian Orelli, PhDThe Big Bet on CorceptWill the FDA approve its Cushing's Syndrome drug, Korlym?
Feb 15, 2012 by Brian Orelli, PhDBioSante's Consolation PrizeAn approval, but not for the potential blockbuster.
Feb 15, 2012 by Brian Orelli, PhDMeet the Branded-Generic-OTC DrugmakerTeva Pharmaeuticals diversifies.
Feb 14, 2012 by Brian Orelli, PhDFDA Concerns Ruin Biotech's DayChelsea Therapeutics takes a dive after telling investors the FDA is questioning Northera's safety.
Feb 14, 2012 by Brian Orelli, PhDHow Many Drug Sales in 2012?That's the question for Seattle Genetics.
Feb 14, 2012 by Brian Orelli, PhDSacrificing the Cash CowGilead tries to prevent HIV infection … which could kill sales of its treatments for the infected.
Feb 10, 2012 by Brian Orelli, PhDAll Good Things Must Come to an EndMomenta will go back to its losing ways.
Feb 9, 2012 by Brian Orelli, PhDWhen Passing Your Clinical Trial Isn't EnoughSide effects ruin Amgen's day in front of the advisory committee.
Feb 8, 2012 by Brian Orelli, PhDModified Study, Same Bloody ResultsMerck's vorapaxar still causing bleeding.
Feb 7, 2012 by Brian Orelli, PhDCan Amgen Convince Docs to Recommend Approval?It's going to be an uphill battle.
Feb 6, 2012 by Brian Orelli, PhDMerck Investors Can Sleep Easier (Not Easy)Merck's insomnia drug suvorexant is on track.
Feb 3, 2012 by Brian Orelli, PhDCuring Diseases Makes For a Bad Business ModelVertex got to a lot of patients quickly, but now what?
Feb 2, 2012 by Brian Orelli, PhDThe Disadvantage of a Successful PipelineBiogen ramps up R&D spending.
